drugset / Trial / NCT04380103
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The phase I/II study was designed to evaluate if the regimen of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab is a superior first-line option for patients with metastatic colorectal cancer(mCRC) in terms of safety and efficacy.
Timeline
- Start
- 2020-04-26
- Primary completion
- 2020-12
- Completion
- 2022-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 165 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |